Today: 7 February 2026
Subscribe
Browse Category

NYSE:LLY News 13 January 2026 - 16 January 2026

Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed

Eli Lilly stock slides premarket after FDA sets April 10 target for weight-loss pill decision, GLP-1 lawsuit filed

New York, January 16, 2026, 05:24 EST — Premarket Eli Lilly and Co shares slipped 3.8% in premarket trading Friday, following a wave of regulatory and legal news around its obesity drugs late last week. The stock last traded at $1,032.97. These shifts are crucial since Lilly’s valuation now hinges on the outlook for its upcoming obesity drugs and how long demand lasts for its existing blockbusters. Delays or new legal battles over access could quickly alter investor growth forecasts. Traders are recalibrating after a week packed with healthcare news, shifting focus to the next moves from regulators and upcoming
16 January 2026
····
Eli Lilly stock slides after FDA pushes obesity pill decision to April 10

Eli Lilly stock slides after FDA pushes obesity pill decision to April 10

New York, Jan 15, 2026, 16:43 (EST) — After-hours Eli Lilly and Co shares dropped 3.8% to $1,032.97 in after-hours trading Thursday after Reuters reported the FDA is now aiming for an April 10 decision on Lilly’s experimental obesity drug, orforglipron. The report also revealed delays in other drugs under a new fast-track review program, following safety and efficacy concerns raised by FDA scientists. (Reuters) The timing is crucial because orforglipron is an oral GLP-1 drug — a pill form of a class that’s transformed obesity and diabetes treatment by imitating a gut hormone to suppress appetite and control blood
15 January 2026
····
Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

Pfizer stock dips as U.S. vaccine policy fight rattles demand outlook

New York, Jan 15, 2026, 11:16 EST — Regular session. Pfizer Inc. shares fell 0.6% to $25.42 in late-morning trading on Thursday, extending a choppy start to the year for the drugmaker’s stock. The stock has struggled to find a clear driver since Pfizer warned in December that 2026 would likely start “bumpy,” with lower COVID-related sales, price cuts tied to a U.S. government deal and key patent expirations looming. Loss of exclusivity is shorthand for patents ending, which can open the door to cheaper rivals. (Reuters) The political noise around vaccines is back in focus. Sanofi Chief Executive Paul
15 January 2026
·········
Why Eli Lilly stock is down today: FDA pushes obesity pill decision to April 10

Why Eli Lilly stock is down today: FDA pushes obesity pill decision to April 10

New York, Jan 15, 2026, 12:06 (EST) — Regular session Eli Lilly and Company shares dropped 4.7% to $1,022.50 on Thursday after Reuters reported that internal documents revealed U.S. regulators delayed a decision on the drugmaker’s weight-loss pill until April 10. A Lilly spokesperson said approval could still come in the second quarter, aligning with current FDA guidance. Holly Fernandez Lynch, a health-policy professor at the University of Pennsylvania, commented on the FDA’s cautious stance, saying, “Hold on, we’re not actually sure this product should be allowed on the market,” highlighting the agency’s readiness to slow fast-tracked reviews. (Reuters) The
15 January 2026
····
Eli Lilly stock dips after hours as FDA seeks label change for Zepbound, traders eye obesity pill push

Eli Lilly stock dips after hours as FDA seeks label change for Zepbound, traders eye obesity pill push

NEW YORK, Jan 14, 2026, 6:33 PM EST — After-hours Eli Lilly shares slipped in after-hours trading Wednesday, as investors digested a U.S. regulatory update on weight-loss drug labels alongside new marketing chatter about the company’s upcoming obesity treatment. The FDA’s move to remove suicide warnings from GLP-1 weight-loss drugs comes at a tricky time for the sector. Demand is surging, competition is ramping up, and any change in safety signals could sway both prescribing habits and payer decisions. For Lilly, the timing coincides with efforts to expand its obesity franchise beyond injections. Traders are eyeing whether an oral pill
15 January 2026
····
Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

Structure Therapeutics stock jumps as Novo deal talk lifts obesity-drug names

New York, January 14, 2026, 13:46 EST — Regular session Shares of Structure Therapeutics (GPCR) jumped roughly 7.5% Wednesday, as traders returned to small-cap obesity drugmakers. The stock climbed to $83.76, trading over 1 million shares. This shift is crucial as investors wager the weight-loss craze will move from weekly injections to pills, reshaping the buyout landscape. A Novo Nordisk executive told Reuters that oral pills might claim “a third-plus” of the GLP-1 market by 2030. (Reuters) Deal rumors picked up steam on Wednesday after a Bloomberg report, highlighted by TheFly, quoted Novo Nordisk CEO Mike Doustdar saying, “We’re in
14 January 2026
········
Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

Pfizer stock rises as CEO likens obesity-drug boom to Viagra ahead of Feb. 3 earnings

NEW YORK, Jan 14, 2026, 11:47 EST — Regular session Pfizer Inc shares climbed Wednesday following CEO Albert Bourla’s renewed commitment to fast-track obesity drugs, a crucial focus as the company navigates patent losses and adjusts post-COVID. This move is crucial as investors demand evidence that Pfizer can develop fresh growth drivers ahead of a tough run of patent expirations. Obesity remains one of the few treatment areas attracting significant investment and rapid uptake, though competition is already fierce. At this week’s J.P. Morgan Healthcare Conference, Bourla laid out expectations for the year ahead as traders focus on whether pipeline
14 January 2026
·····
Eli Lilly stock slips as FDA drops suicide warning for Zepbound; traders eye orforglipron, earnings next

Eli Lilly stock slips as FDA drops suicide warning for Zepbound; traders eye orforglipron, earnings next

New York, Jan 14, 2026, 11:40 AM EST — Regular session Eli Lilly and Company shares slipped Wednesday following a move by U.S. regulators to remove suicide-related warnings from several popular obesity drugs, including Lilly’s Zepbound. The stock was down roughly 0.4%, trading near $1,072.89 by late morning. (U.S. Food and Drug Administration) The label change is significant because it addresses a major safety concern that’s been dogging weight-loss drugs, even as demand remains robust and politicians and insurers press on prices. For Lilly, obesity remains the key driver in the stock, and anything that cuts “headline risk” usually gets
14 January 2026
·····
Eli Lilly stock in focus after hours as FDA moves on Zepbound label and pill race tightens

Eli Lilly stock in focus after hours as FDA moves on Zepbound label and pill race tightens

New York, Jan 13, 2026, 18:23 EST — After-hours Eli Lilly and Company shares were down 0.4% at $1,077.19 in after-hours trading on Tuesday. The U.S. Food and Drug Administration asked drugmakers to remove suicide-related warnings from labels of GLP-1 weight-loss drugs — medicines that mimic a gut hormone to curb appetite — including Lilly’s Zepbound. (Reuters) The label shift matters because investors still treat safety language as a proxy for how wide these drugs can spread, and how quickly. Obesity drugs have turned into a crowded, high-stakes market where small changes in risk perception can move demand, and pricing
14 January 2026
····
Nvidia stock stays flat after China tightens H200 chip approvals; Eli Lilly $1B AI lab grabs attention

Nvidia stock stays flat after China tightens H200 chip approvals; Eli Lilly $1B AI lab grabs attention

New York, January 13, 2026, 4:03 PM ET — After-hours NVIDIA Corporation shares (NVDA) barely moved Tuesday following a report that China is restricting approvals for buying the company’s H200 AI chips. The stock last dipped 0.04% to $184.87 shortly after the close, after bouncing between $183.45 and $188.08. (Reuters) The China headlines are key because the H200 — a top-tier graphics processing unit (GPU) used in data centers for training and running AI models — is central to Nvidia’s growth narrative. According to the report, Beijing’s guidance to some companies was “deliberately vague,” advising purchases only when “necessary.” More
13 January 2026
······
Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

Eli Lilly stock (LLY) edges up as FDA clears GLP-1 label cloud; $150 pill launch looms

New York, Jan 13, 2026, 11:51 EST — Regular session Shares of Eli Lilly and Company inched up 0.2% to $1,083.63 on Tuesday, fluctuating between $1,070 and $1,090 as roughly 736,000 shares exchanged hands. The move followed the U.S. Food and Drug Administration’s request that drugmakers strip suicide-related warnings from labels on GLP-1 weight-loss medications, including Lilly’s Zepbound and Novo Nordisk’s Wegovy. (Reuters) The request matters because safety language on labels can influence how quickly doctors prescribe and how confident insurers feel about coverage. In a market already clogged with supply and demand chatter, even minor shifts in perceived risk
13 January 2026
····
Nvidia stock barely budges after H200 China payment reset; Lilly AI lab plan in focus

Nvidia stock barely budges after H200 China payment reset; Lilly AI lab plan in focus

NEW YORK, Jan 13, 2026, 09:36 ET — Regular session Nvidia shares held steady in early New York trading Tuesday after the company announced it won’t require upfront payments for its H200 AI chips. The stock ticked up just 0.03% to $184.94. (Reuters) This is a sensitive subject since any suggestion of stricter rules in China might come across as a demand or regulatory red flag for a company whose latest chips have become essential for AI data centers. Extra payment hurdles can stall bookings and delay deliveries, even when customers are eager for the chips. For a stock valued
13 January 2026
······
1 … 3 4 5 6 7 … 13

Stock Market Today

Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

Vodafone shares steady up after Q3 wobble — Germany, buyback and next results now set the tone

7 February 2026
Vodafone shares rose 1.47% to 110.60p Friday, recovering part of Thursday’s 4.68% drop after a Q3 update. Group revenue climbed 6.5% to €10.5 billion, but Germany’s 0.7% service revenue growth missed some forecasts. Vodafone launched a new €500 million buyback tranche, bringing total buybacks since May to €3.5 billion. Investors remain focused on Germany’s pace and cash flow execution.
NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

NatWest Group stock: buyback filing and Rightmove mortgage deal set up a busy week

7 February 2026
NatWest shares closed up 1.45% at 659.4 pence Friday, buoyed by a buyback of 797,428 shares and a new digital mortgage deal with Rightmove. The Bank of England held rates at 3.75% but signaled possible cuts, with markets pricing in two reductions for 2026. NatWest plans to expand its Accelerator community to 50,000 members by 2026. Annual results are due Feb. 13.
Unilever share price holds at 5,250p as results week looms — what investors watch next

Unilever share price holds at 5,250p as results week looms — what investors watch next

7 February 2026
Unilever shares closed flat at 5,250p in London Friday, underperforming the FTSE 100’s 0.6% gain. The company issued 4.2 million new shares for employee plans, bringing total shares to over 2.18 billion. Investors await Q4 and full-year results on Feb. 12, with analyst consensus pointing to 3.9% Q4 sales growth. Unilever’s U.S. ADR rose 0.8% to $72.12.
BP share price near 52-week high ahead of Feb 10 earnings as buyback runs on

BP share price near 52-week high ahead of Feb 10 earnings as buyback runs on

7 February 2026
BP shares closed up 1.9% at 478 pence Friday, just below a 52-week high, as the company continued buybacks ahead of next week’s results. BP repurchased 2.789 million shares on February 6. Oil prices firmed on geopolitical risk, with Brent at $68.05 a barrel, but sector outlook remains uncertain. Investors await BP’s earnings and dividend decision due Tuesday.
Go toTop